Pfizer
VC Fund
New York, United States
Pfizer is a VC fund in New York focused on Biotechnology and Health Care. Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Pfizer invests in
Stages Pfizer invests in
Countries Pfizer invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $800k–$11M
- Series A
- $4.5M–$412M
- Post-IPO Equity
- $25M–$320M
Investment Focus
Industry
- Biotechnology 34 (61%)
- Health Care 26 (46%)
- Pharmaceutical 18 (32%)
- Therapeutics 14 (25%)
- Medical 13 (23%)
Stage
- Series A 9 (16%)
- Post-IPO Equity 9 (16%)
- Seed 6 (11%)
- Series B 6 (11%)
- Corporate Round 6 (11%)
Country
- United States 26 (46%)
- Israel 5 (9%)
- France 2 (4%)
- Belgium 2 (4%)
- Switzerland 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alessandra Leone
Global CMC Sr. Manager
|
Global CMC Sr. Manager | Total investments: 0 | Find email | |
|
Angela L Coral
Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact
|
Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact | Total investments: 0 | Find email | |
Barbara Dalton
Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development
|
Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development | Total investments: 9 | Find email | |
Chris Boshoff
CSO
|
CSO | Total investments: 1 | Find email | |
Chris O’Donnell
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation
|
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation | Total investments: 4 | Find email | |
| See all 22 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CellCentric
|
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M / Series D / May 06, 2026 | |
RNT Health Insights
|
RNT Health Insights developing an AI-assisted tool to aid endoscopists in the real-time detection of upper gastrointestinal lesions. | Pre-Seed / Dec 30, 2024 | |
|
RNT Health Insights
|
RNT Health Insights developing an AI-assisted tool to aid endoscopists in the real-time detection of upper gastrointestinal lesions. | Grant / Nov 11, 2024 | |
Promise Bio
|
Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases. | $8.3M / Seed / Oct 23, 2024 | |
CytoReason
|
CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology. | $80M / Series B / Jul 17, 2024 | |
EvolveImmune Therapeutics
|
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M / Venture - Series Unknown / Nov 16, 2023 | |
AgomAb Therapeutics
|
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M / Series C / Oct 11, 2023 | |
|
CellCentric
|
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $25M / Corporate Round / Jul 11, 2023 | |
Caribou Biosciences
|
Caribou Biosciences is a operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development oftherapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research. | $25M / Post-IPO Equity / Jun 29, 2023 | |
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | |
| See all 56 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pfizer invest in?
Pfizer invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Post-IPO Equity stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pfizer's check size?
Pfizer typically joins rounds of $800k–$11M at Seed, $4.5M–$412M at Series A and $25M–$320M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pfizer participates in.
How do I contact Pfizer?
Public channels for Pfizer include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pfizer?
The team at Pfizer includes Alessandra Leone (Global CMC Sr. Manager), Angela L Coral (Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact) and Barbara Dalton (Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development), among 22 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
